Apogee Therapeutics Executive Compensation (FY25)
APGE · Executive and director compensation, fiscal 2023 to 2025
The paid brief on Apogee Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 9, 2026Latest filing (DEF 14A): April 24, 2026
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
72 figures on this page, cited to the filing that reported them. See the citations
More on Apogee Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Henderson: $13,207,682 → $1,291,500 (90.2% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Apogee Therapeutics' chief executive and what were they paid?
Total compensation for Michael Henderson, Chief Executive Officer, came to $1,291,500 in fiscal 2025. Henderson's total was 90.2% lower than the $13,207,682 reported for fiscal 2024.
Which companies are in Apogee Therapeutics' peer group?
The disclosed peer group names Akero Therapeutics, Arcellx, Arrowhead Pharmaceuticals, Avidity Biosciences and Celldex Therapeutics, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Henderson Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Henderson Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Henderson Chief Executive Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Carl Dambkowski Chief Medical Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Michael Henderson | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 12/9/2034 | |
| Option | ◇ | — | ◇ | 12/18/2033 | |
| Jane Henderson | Option | ◇ | — | ◇ | 12/18/2033 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 12/9/2034 | |
| Carl Dambkowski | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 12/9/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 12/18/2033 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Mark C. McKenna Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Jennifer Fox | ◇ | — | ◇ | — | — | — | ◇ |
William (BJ) Jones Jr | ◇ | — | ◇ | — | — | — | ◇ |
Peter Harwin | ◇ | — | ◇ | — | — | — | ◇ |
Andrew Gottesdiener, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Nimish Shah | ◇ | — | ◇ | — | — | — | ◇ |
Lisa Bollinger, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Tomas Kiselak | ◇ | — | ◇ | — | — | — | ◇ |
Michael Henderson, M.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Akero Therapeutics AKRO
- Arcellx ACLX
- Arrowhead Pharmaceuticals ARWR
- Avidity Biosciences RNA
- Celldex Therapeutics CLDX
- Dyne Therapeutics DYN
- IDEAYA Biosciences IDYA
- Immunovant IMVT
- Kymera Therapeutics KYMR
- Neumora Therapeutics NMRA
- Nuvalent NUVL
- Spyre Therapeutics SYRE
- Structure Therapeutics GPCR
- Vaxcyte PCVX
- Viking Therapeutics VKTX
What this page does not include
Everything above is a fact Apogee Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Apogee Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
72 figures on this page, cited to the filing that reported them.
72 cited to the filing
Documents cited
- 0001193125-26-177342
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Apogee Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/APGE (accessed 2026).
Short form: data: Velarion
The paid brief for Apogee Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Apogee Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Apogee Therapeutics discloses
The companies named in APGE's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}